Business Information
The group's principal activities are to design and develop new class of drugs for the treatment of acute and chronic inflammatory diseases, infectious diseases and cancer. The group has a broad proprietary position covering epitope identification system, numerous epitopes for cancer and infectious disease vaccine targets and other vaccine technology. Epimmune(tm) , eis(tm), epigene(tm) and padre(tm) are the trademarks and immunosense is a service mark of the company. The group is in the research and preclinical development with therapeutic vaccines for breast, colon, lung and prostate cancers, hepatitis c, HIV and malaria.
|
|
Name |
Title
|
Email
|
| Sylvie Gregoire | Executive Chairperson | N/A | | Herve De Lamotte Duchesne | Acting Principal Financial, Accounting Officer - Principal Financial, Accounting Officer | N/A | | Robert De Vaere | Sr. VP - Finance, Administration, CFO | N/A | | Bonnie Mills | VP - Clinical Operations | N/A | | Jeffrey Sherman | Sr. VP - Research, Development, Chief Medical Officer | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 11,286 | (23,455) | | 2005 | 8,539 | (39,209) | | 2004 | 9,647 | (3,882)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
